Table 2 Medical therapies used prior to start of LDN and concomitantly with LDN
From: Low dose Naltrexone for induction of remission in inflammatory bowel disease patients
| Â | UC, 19 | CD, 28 | Combined, 47 |
|---|---|---|---|
Prior and concomitant therapies | |||
 Therapies prior to LDN, N (%) | |||
  5-ASA | 17 (89%) | 14 (50%) | 31 (66%) |
  Steroids | 19 (100%) | 28 (100%) | 47 (100%) |
  Immunosuppressives | 18 (95%) | 27 (96%) | 45 (96%) |
  Anti-TNF | 16 (84%) | 25 (89%) | 41 (87%) |
  Other | 5 (26%) | 2 (7%) | 8 (15%) |
 Concomitant therapies at start of LDN, N (%) | |||
  5-ASA | 7 (37%) | 3 (11%) | 10 (21%) |
  Steroids | 6 (32%) | 18 (64%) | 24 (51%) |
  Immunosuppressives | 8 (42%) | 9 (32%) | 17 (36%) |
  Anti-TNF | 5 (26%) | 3 (11%) | 8 (17%) |
  Other | 1 (5%) | 2 (7%) | 3 (6%) |
  None | 4 (21%) | 7 (25%) | 11 (23%) |